81624-55-7 Usage
Uses
Used in Pharmaceutical Industry:
NSC-348884 is used as a potential anticancer agent for its ability to target and disrupt the formation of NPM oligomers, which are often associated with the development and progression of various types of cancer. By inhibiting these oligomers, NSC-348884 can help prevent the uncontrolled cell growth and division that characterizes cancer.
Furthermore, NSC-348884 is used to upregulate the expression of the p53 protein, a well-known tumor suppressor that plays a crucial role in preventing the development of cancer. By increasing the levels of p53, NSC-348884 can enhance the cell's ability to detect and repair DNA damage, thereby reducing the likelihood of cancerous mutations.
In addition to its effects on NPM oligomers and p53, NSC-348884 is also used to induce apoptosis, or programmed cell death, in cancer cells. This is an important mechanism for eliminating damaged or abnormal cells, and by promoting apoptosis, NSC-348884 can help to prevent the growth and spread of cancer.
Overall, NSC-348884's multifaceted approach to cancer treatment, targeting NPM oligomer formation, upregulating p53, and inducing apoptosis, positions it as a valuable asset in the development of novel cancer therapies.
Biological Activity
nsc348884 is a nucleophosmin inhibitor.nucleophosmin is identified as a multifunctional nucleolar phosphoprotein, which is dysregulated in human malignancies resulting in anti-apoptosis and differentiation inhibition.
in vitro
nsc348884, which was identified as a putative nucleophosmin small molecular inhibitor, was found to be able to disrupt a hydrophobic pocket that was required for oligomerization, and nsc348884 could also inhibit the cell proliferation in distinct cancer cell lines and disrupt nucleophosmin oligomer formation. moreover, the treatment of several cancer cell types with nsc348884 could dose-dependently upregulate p53 and also induce apoptosis that correlated with h2ax phosphorylation, poly(adp-ribose) polymerase cleavage as well as annexin v. furthermore, nsc348884 could also synergize doxorubicin cytotoxicity on the viability of cancer cells [1].
in vivo
previous study showed that the in-vivo intravasation and invasion could be significantly inhibited after the injection of nsc348884 into the tumor-bearing mice. in addition, there was no significant difference in overall cell death that was observed by histology in the treated tumors with the 4-hour brief treatments, indicating that the inhibition seen was specific to migration [2].
IC 50
1.7-4.0 μm for tested cancer cell lines
references
[1] qi w,shakalya k,stejskal a,goldman a,beeck s,cooke l,mahadevan d. nsc348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. oncogene.2008 jul 10;27(30):4210-20. [2] patsialou a,wang y,lin j,whitney k,goswami s,kenny pa,condeelis js. selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. breast cancer res.2012 oct 31;14(5):r139.
Check Digit Verification of cas no
The CAS Registry Mumber 81624-55-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,6,2 and 4 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 81624-55:
(7*8)+(6*1)+(5*6)+(4*2)+(3*4)+(2*5)+(1*5)=127
127 % 10 = 7
So 81624-55-7 is a valid CAS Registry Number.
81624-55-7Relevant academic research and scientific papers
INHIBITORS OF NUCLEOPHOSMIN (NPM) AND METHODS FOR INDUCING APOPTOSIS
-
Page/Page column 7-8, (2008/12/08)
Nucleophosmin inhibitors are disclosed which inhibit the multimerization of nucleophosmin and the biological activity of nucleophosmin, such as the ability of nucleophosmin to inhibit apoptosis and inhibit cellular differentiation. These small molecule inhibitors are useful for treating diseases and disorders, such as cancer associated with dysregulated nucleophosmin expression. Methods for identifying small molecule inhibitors of nucleophosmin involving multimerization sites for nucleophosmin are also disclosed. An exemplary small molecule inhibitor of nucleophosmin is NSC348884 which has the following chemical structure:
